Date: 2017-12-04
Type of information: Nomination
Compound: vice-president - chief medical officer
Company: Cellectis (France)
Therapeutic area: Cancer - Oncology - Rare diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On December 4, 2017, Cellectis announced the appointment of Prof. Stéphane Depil, MD, PhD, to the role of Senior Vice President Research & Development and Chief Medical Officer. Prof. Depil’s responsibilities include bringing Cellectis' product candidates to clinical-stage development, strategic and operational management of all therapeutic activities, and supervising research and development projects for the company. Stéphane Depil will keep academic and research activities as adjunct Professor at Léon Bérard Cancer Center & University Claude Bernard Lyon 1.
- Prof. Depil is a board-certified physician in hematology, with over 15 years of experience in oncology clinical development, both in hospital / university and pharmaceutical companies. Prior to joining the Léon Bérard Cancer Center & Cancer Research Center of Lyon, France as Medical Director of the Cancer Immunotherapy Program, he served as Chief Executive Officer at Netris Pharma, where he was responsible for the management of an oncology startup and preclinical development of a first-in-class monoclonal antibody in Phase I. Prior to Netris, Stéphane Depil worked at Servier for 8 years in a variety of roles, including Director of Oncology Research and Development, where he managed 20 programs: 5 in the clinic, 7 at late preclinical stages, and 8 at
early preclinical stages. He also directly supervised over 100 licensing opportunities.
Financial terms:
Latest news:
Is general: Yes
